← All trials
NCT01868906
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2013
- Primary completion
- Dec 1, 2018
- Completion date
- Jun 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Dr. Negrin University HospitalLead sponsor
- Mario Negri InstituteOverall official - principal investigator
- Mario Negri InstituteSponsor investigator
- Mario Negri InstituteStudy chair
- Grupo de Investigación Clínica en Oncología RadioterapiaCollaborator
- RSbiomedCollaborator
- Fundación DISA, Canary Islands, SpainCollaborator
- Universidad Carlos III MadridCollaborator
- University of Texas at HoustonOverall official - principal investigator
- University of Texas at HoustonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.